| Literature DB >> 32160913 |
Rony Kayrouz1,2, Eyal Karin3,4, Lauren G Staples3,4, Olav Nielssen3, Blake F Dear3,4, Nickolai Titov3,4.
Abstract
BACKGROUND: To explore the characteristics and compare clinical outcomes of non-Australian born (migrant) and Australian-born users of an Australian national digital mental health service.Entities:
Keywords: Anxiety; Depression; Digital mental health service; Ethnicity; Migrants; Online treatment; iCBT
Year: 2020 PMID: 32160913 PMCID: PMC7065305 DOI: 10.1186/s12888-020-02486-3
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Fig. 1Sample sizes of patients at assessment and treatment. Note. ESB Migrant = Migrant of an English Speaking Background (e,g., England, New Zealand, United States of America etc); NESB Asia = Migrant from the Asian Region (e.g., China, Malaysia, India etc); NESB Europe = Migrants from the Europe region (e.g., Italy, Spain, Greece, Germany etc); NESB MidEast = Migrant from the Middle Eastern or North Africa Region (e.g., Lebanon, Iraq, Egypt etc),; NESB Migrant = Migrant of a Non-English Speaking Background
Demographic Characteristics, Symptom Scores and Mental Health Service Use of the Cohorts at Treatment
| Migrants by Language Regions | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AusBorn | NESB MidEast | NESB Europe | NESB Asia | NESB English | ESB English | Nagelkerke R Square associated with cohort differences | ||||||||
| n | 5151 | 74% | 43 | 1% | 115 | 2% | 182 | 3% | 323 | 5% | 930 | 13% | ||
| Males | 1365 | 27% | 22 | 51% | 27 | 23% | 70 | 38% | 79 | 25% | 270 | 29% | .007 | 0.2% |
| 18–24 | 527 | 10% | 3 | 7% | 1 | 1% | 11 | 6% | 22 | 7% | 46 | 5% | .016 | 0.7% |
| 25–40 | 2567 | 50% | 27 | 63% | 73 | 63% | 128 | 70% | 162 | 50% | 394 | 42% | 0.8% | |
| 40–65 | 2053 | 40% | 13 | 30% | 41 | 36% | 43 | 24% | 138 | 43% | 490 | 53% | 1.0% | |
| Rural Location | 1181 | 23% | 0 | 0% | 8 | 7% | 2 | 1% | 38 | 12% | 154 | 17% | 2.2% | |
| Unemployed | 1307 | 25% | 17 | 40% | 38 | 33% | 43 | 24% | 94 | 29% | 230 | 25% | .10 | 0.2% |
| Employed | 3442 | 67% | 18 | 42% | 68 | 59% | 121 | 67% | 207 | 64% | 667 | 72% | .001 | 0.4% |
| Student | 402 | 8% | 8 | 19% | 9 | 8% | 17 | 9% | 22 | 7% | 33 | 4% | 1.1% | |
| High School or less | 784 | 15% | 0 | 0% | 8 | 7% | 2 | 1% | 26 | 8% | 100 | 11% | 2.2% | |
| Adult Education | 1884 | 37% | 6 | 14% | 33 | 29% | 19 | 10% | 104 | 32% | 346 | 37% | 1.6% | |
| University Education | 2483 | 48% | 37 | 86% | 74 | 64% | 161 | 88% | 193 | 60% | 484 | 52% | 3.4% | |
| Work/Study Difficulties | 3843 | 75% | 34 | 78% | 94 | 82% | 151 | 83% | 241 | 74% | 721 | 78% | .059 | 0.3% |
| Relationship Difficulties | 3187 | 62% | 24 | 56% | 81 | 70% | 123 | 67% | 215 | 66% | 593 | 64% | 0.2% | |
| Health Difficulties | 2968 | 58% | 18 | 41% | 63 | 55% | 98 | 54% | 166 | 51% | 518 | 56% | .13 | 0.1% |
| Financial Difficulties | 2602 | 51% | 23 | 55% | 67 | 59% | 79 | 43% | 162 | 50% | 492 | 53% | .31 | 0.1% |
| Mental Health Service Use | 3876 | 75% | 19 | 44% | 77 | 67% | 89 | 49% | 224 | 69% | 694 | 75% | 1.4% | |
| Clinical levels of PHQ9 symptoms | 3796 | 74% | 28 | 65% | 84 | 73% | 120 | 66% | 236 | 73% | 699 | 75% | .16 | 0.1% |
| Clinical levels of GAD7 symptoms | 4063 | 79% | 34 | 79% | 84 | 73% | 126 | 69% | 236 | 73% | 728 | 78% | .006 | 0.0% |
| Treatment Completion Rate | 67% | 3852 | 78% | 31 | 67% | 68 | 59% | 72 | 70% | 190 | 77% | 530 | 0.8% | |
| Average lesson completion (of 5) | 3.86 | 3.88 | 3.76 | 3.58 | 3.96 | 4.06 | 0.4% | |||||||
| Missing cases at Post-treatment | 1943 | 38% | 18 | 42% | 44 | 38% | 76 | 42% | 117 | 36% | 283 | 30% | 0.1% | |
| Years since arrival to Australia (0-5 yrs) | – | – | 16 | 37% | 31 | 27% | 37 | 21% | 38 | 12% | 221 | 24% | 3.3% | |
| Years since arrival (5-10 yrs) | – | – | 9 | 21% | 29 | 25% | 65 | 36% | 55 | 17% | 147 | 16% | 2.8% | |
| Years since arrival (10+ yrs) | – | – | 18 | 42% | 55 | 48% | 80 | 44% | 230 | 71% | 562 | 60% | 4.8% | |
Note. Aus Australian, Ax Assessment, ESB English Speaking Background, Europe Europe region, GAD7 Generalized Anxiety Disorder Scale (7-item), MidEast Middle Eastern or North Africa Language Region, n cohort sample size NESB Non-English Speaking Background, PHQ9 Patient Health Questionnaire (9-item), Tx Treatment, yrs. years
Fig. 2Characteristics of Cohorts at Treatment. Note. Aus = Australian; Ax = Assessment; ESB = English Speaking Background; Europe = Europe region; GAD7 = Generalised Anxiety Disorder Scale (7-item); MHuse = mental health service use; MidEast = Middle Eastern or North African Region; NESB = Non-English Speaking Background; PHQ9 = Patient Health Questionnaire (9-item); Tx = Treatment; yrs. = years
Fig. 3Depressive symptom scores and percentage change. Note. Aus = Australian; ESB = English Speaking Background; Europe = Europe region; MidEast = Middle Eastern or North African Region; NESB = Non-English Speaking Background; PHQ9 = Patient Health Questionnaire (9-item); Pre-Post = Pre-treatment to Post-treatment; Tx = Treatment; Δ = Change
Fig. 4Anxiety symptom scores and percentage change. Note. Aus = Australian; ESB = English Speaking Background; Europe = Europe region; GAD7 = Generalised Anxiety Disorder Scale (7-item); MidEast = Middle Eastern or North African Region; NESB = Non-English Speaking Background; Pre-Post = Pre-treatment to Post-treatment; Tx = Treatment; Δ = Change
Post-treatment Change in Primary Outcomes
| PHQ9 | Pre EMM [95%CI] | Post EMM [95%CI] | ∆%@ Pre-Post [95%CI] | Test of baseline scores differences ( | Test of rate of change ( | Achieved statistical power | Within group ES -Hedge’s g pre-post [95%CI] | Between group ES - Hedge’s g @post [95%CI] | Between group ∆% @ Pre-Posta |
|---|---|---|---|---|---|---|---|---|---|
| NESB MidEast | 12.88 [10.96, 14.81] | 6.33 [4.47, 8.19] | 51% [36, 65%] | .46 | .68 | 20% (β = − 0.84) | 1.13 [0.95, 1.32] | 0.16 [0.04, 0.28] | 11% [−20, 35%] |
| NESB Europe | 13.05 [12.01, 14.1] | 7.3 [6.28, 8.31] | 44% [36, 52%] | .29 | .38 | 20% (β = − 0.84) | 1.08 [0.97, 1.2] | −0.03 [− 0.1, 0.05] | −2% [−19, 12%] |
| NESB Asia | 12.79 [11.92, 13.67] | 5.78 [4.72, 6.85] | 55% [46, 63%] | .069 | .12 | 40% (β = − 0.25) | 1.35 [1.26, 1.45] | 0.26 [0.2, 0.32] | 19% [2, 33%] |
| NESB English | 13.69 [13.06, 14.32] | 6.87 [6.23, 7.51] | 50% [45, 54%] | .88 | .46 | 30% (β = −0.52) | 1.28 [1.21, 1.35] | 0.05 [0.01, 0.1] | 4% [−8, 14%] |
| ESB English | 13.48 [13.14, 13.83] | 6.32 [6.0, 6.63] | 53% [51, 56%] | .41 | .001 | 90% (β = 1.28) | 1.43 [1.39, 1.47] | 0.15 [0.12, 0.18] | 11% [6, 17%] |
| AusBorn | 13.64 [13.49, 13.8] | 7.13 [6.82, 7.43] | 48% [46, 50%] | – | – | – | 1.2 [1.18, 1.22] | – | – |
| GAD7 | Pre EMM (95%CI) | Post EMM (95%CI) | ∆%@ Pre-Post [95%CI] | Test of baseline scores differences ( | Test of rate of change ( | Achieved statistical power | Within group ES -Hedge’s g pre-post [95%CI] | Between group ES - Hedge’s g @post [95%CI] | Between group ∆% @ Pre-Posta [95%CI] |
| NESB MidEast | 11.44 [9.8, 13.09] | 5.58 [3.16, 8] | 51% [30, 72%] | .53 | .071 | 20% (β = −0.84) | 1.09 [0.91, 1.28] | 0.16 [0.04, 0.28] | 12% [−35, 42%] |
| NESB Europe | 11.91 [10.95, 12.87] | 6.75 [5.31, 8.19] | 43% [31, 55%] | .88 | .45 | 20% (β = −0.84) | 1.07 [0.95, 1.18] | −0.11 [− 0.19, − 0.04] | −8% [−34, 14%] |
| NESB Asia | 11.43 [10.68, 12.18] | 5.18 [4.49, 5.87] | 55% [49, 61%] | .16 | .057 | 25% (β = − 0.68) | 1.39 [1.3, 1.49] | 0.25 [0.19, 0.31] | 17% [4, 29%] |
| NESB English | 11.55 [10.99, 12.11] | 6.19 [5.56, 6.81] | 46% [41, 52%] | .14 | .59 | 30% (β = −0.52) | 1.12 [1.06, 1.19] | 0.02 [−0.03, 0.06] | 1% [−8, 10%] |
| ESB English | 11.83 [11.53, 12.13] | 5.72 [5.45, 5.99] | 52% [49, 54%] | .35 | .006 | 90% (β = 1.28) | 1.37 [1.33, 1.41] | 0.12 [0.09, 0.15] | 9% [4, 13%] |
| AusBorn | 11.99 [11.86, 12.12] | 6.26 [6.02, 6.5] | 48% [46, 50%] | – | – | – | 1.25 [1.23, 1.27] | – | – |
Note. The multiple imputation procedure was adjusted for number of lesson completion (approximating treatment dose), time, Cohort group and all possible two way interaction between Dose, time and Cohort; a Reference Group is Ausborn; Aus Australian, EMM Estimated Marginal Means, ESB English Speaking Background, Europe Europe region, GAD7 Generalised Anxiety Disorder Scale (7-item), MI Multiple Imputations, MidEast Middle Eastern or North Africa Region, NESB Non-English Speaking Background, PHQ9 Patient Health Questionnaire (9-item), Post Post-treatment, Pre Pre-treatment, Δ Change
Fig. 5Proportions of individuals with four clinical categories.Note. Aus = Australian; ESB = English Speaking Background; Europe = Europe region; GAD7 = Generalised Anxiety Disorder Scale (7-item); MidEast = Middle Eastern or North African Region; NESB = Non-English Speaking Background; PHQ9 = Patient Health Questionnaire (9-item); Post = Post-treatment
Deterioration, Non-response, Minimal Response and Remission Rates
| Bootstrapped PHQ9 categories of ∆@ Pre-Post | Nonresponse (−30 to 30%) | Deterioration (> − 30%) | Differences in proportions from AusBorn group (Bootstrapped | |||||
|---|---|---|---|---|---|---|---|---|
| Remission (> 50%) | Minimal Response (30–50%) | Remission | Minimal Response | Nonresponse | Deterioration | |||
| NESB MidEast | 64% | 20% | 16% | 0% | .41 | .88 | .56 | .99 |
| NESB Europe | 56% | 13% | 25% | 6% | .92 | .19 | .35 | .70 |
| NESB Asia | 62% | 22% | 12% | 4% | .18 | .46 | .035 | .67 |
| NESB English | 58% | 23% | 14% | 6% | .58 | .16 | .017 | .53 |
| ESB English | 61% | 19% | 18% | 3% | .019 | .89 | .073 | .061 |
| Aus Born | 56% | 19% | 21% | 5% | – | – | – | – |
| Bootstrapped GAD7 categories of ∆@ Pre-Post | Nonresponse | Deterioration | Differences in proportions from AusBorn group (Bootstrapped | |||||
| Remission | Minimal Response | Remission | Minimal Response | Nonresponse | Deterioration | |||
| NESB MidEast | 70% | 17% | 13% | 0% | .18 | .88 | .36 | .99 |
| NESB Europe | 51% | 24% | 20% | 6% | .42 | .26 | .81 | .79 |
| NESB Asia | 68% | 14% | 14% | 4% | .012 | .25 | .093 | .58 |
| NESB English | 53% | 17% | 23% | 7% | .39 | .50 | .42 | .11 |
| ESB English | 57% | 21% | 19% | 4% | .61 | .20 | .25 | .19 |
| Aus Born | 56% | 19% | 21% | 5% | – | – | – | – |
Note. Categories classified as deterioration (> − 30%), non-response (−30 to 30%), minimal response (30 to 50%) and remission (> 50%); Aus Australian, ESB English Speaking Background, Europe Europe region, GAD7 Generalised Anxiety Disorder Scale (7-item), MidEast Middle Eastern or North African Region, NESB Non-English Speaking Background, PHQ9 Patient Health Questionnaire (9-item), Pre-Post Pre-treatment to Post-treatment